MSD is a biopharmaceutical company in Athens, Greece, focused on research-driven medicines and vaccines.
Last updated September 10, 2026
AI crawler reads
2requests
1companies- Anthropic2
- Profile
- 2
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
MSD is a biopharmaceutical company in Athens, Greece. It describes itself as aspiring to be a research-focused biopharmaceutical company with a leading global position, developing innovative solutions for the prevention and treatment of diseases in humans and animals. In Greece, MSD focuses on areas such as oncology, vaccines, hospital care, pulmonary hypertension, and antimicrobial resistance.
History
MSD states that for more than 130 years it has contributed to health through the development of important medicines and vaccines. In Greece, MSD focuses on areas such as oncology, vaccines, hospital care, pulmonary hypertension, and addressing antimicrobial resistance, and it operates in Greece with a stable presence and an active role in supporting health innovation.
Products and positioning
Research-focused biopharmaceutical company with a leading global position, developing innovative solutions for prevention and treatment of diseases in humans and animals.
Oncology
Keytruda (Pembrolizumab)
Oncology
Lynparza (Olaparib)
Oncology
IVEMEND (Fosaprepitant dimeglumine)
Oncology
EMEND (Aprepitant)
Oncology
Temodal (Temozolomide)
Oncology
OncoTICE (Bacillus Calmette-Guerinn (BCG, strain tice))
Oncology
Welireg (Belzutifan)
Vaccines
MMR vaxPro
Vaccines
HBvaxPRO
Vaccines
VAQTA 25U
Vaccines
VAQTA 50U
Vaccines
VARIVAX
Vaccines
RotaTeq
Vaccines
ProQuad
Vaccines
Gardasil 9
Vaccines
Vaxelis
Vaccines
Vaxneuvance
Vaccines
Capvaxive
Endocrinology
Januvia (sitagliptin)
Endocrinology
Janumet (sitagliptin, metformin)
Infectious Diseases
Noxafil (Posaconazole)
Infectious Diseases
Isentress (Raltegravir)
Infectious Diseases
Zerbaxa (ceftolozane, tazobactam)
Infectious Diseases
Cubicin (Daptomycin)
Recent events
Reported
MSD appoints Mary Srethapakdi as Managing Director for the Philippines[6]
MSD in the Philippines, a trade name of Merck & Co., Inc, announced the appointment of Mary Srethapakdi as managing director for the Philippines, while she concurrently leads MSD's operations in Thailand. She succeeds Andreas Riedel, who has been appointed Managing Director for MSD Vietnam.
- Unconfirmed
Reported
NOXXON and MSD collaborate on NOX-A12 study[7]
NOXXON and MSD entered a collaboration for MSD to provide pembrolizumab (Keytruda) and expert advice for the OPTIMUS study of NOX-A12 in second-line pancreatic cancer.
- Unconfirmed
WEHI and MSD establish researcher exchange collaboration[8]
WEHI and MSD established a three-year exchange program under which WEHI researchers can be seconded to MSD’s Research Laboratories; the agreement also gives MSD an exclusive option to license WEHI intellectual property.
Reported
FDA approves Keytruda and Lenvima combination for advanced kidney cancer[9]
The FDA approved MSD's Keytruda and Eisai's Lenvima combination as first-line treatment for adults with advanced renal cell carcinoma.
Reported
BioInvent and MSD enter a clinical-trial collaboration for BI-1808 and KEYTRUDA[10]
BioInvent announced a second clinical-trial collaboration and supply agreement with MSD to evaluate BioInvent’s BI-1808 with MSD’s KEYTRUDA in a Phase 1/2a trial involving patients with lung and ovarian cancer.
Reported
Alkermes and MSD enter clinical trial collaboration[11]
Alkermes announced a clinical trial collaboration and supply agreement with MSD for a planned phase 3 study evaluating nemvaleukin alfa in combination with KEYTRUDA in patients with platinum-resistant ovarian cancer. Alkermes is responsible for conducting the study, which was planned to initiate in the second half of 2021.
Reported
FDA approves Novocure application to initiate KEYNOTE-B36 trial[12]
Novocure reported that the U.S. FDA approved its investigational device exemption application to initiate the KEYNOTE-B36 phase 2 pilot trial studying TTFields with pembrolizumab in first-line non-small cell lung cancer.
Reported
Sanofi and MSD agree to test THOR-707 with Keytruda[13]
Sanofi entered an agreement with MSD to collaborate on a phase II trial evaluating Sanofi's investigational candidate THOR-707 alongside MSD's Keytruda.
Reported
QBiotics and MSD clinical collaboration[14]
QBiotics announced that it had entered into an agreement with MSD to evaluate tigilanol tiglate in combination with Keytruda in patients with unresectable melanoma.
Reported
MSD announces plan to acquire Takeda’s Dunboyne facility[15]
MSD announced plans to acquire Takeda’s biologics manufacturing plant in Dunboyne, Ireland. The companies expected the staff consultation and transfer process to be completed in mid-September; the acquisition was not reported as completed.
Sources18 sources
- 1Homepage - MSDmsd.gr
- 2Τα Προϊόντα μας - MSDmsd.gr
- 3Σχετικά Με Εμάς - MSDmsd.gr
- 4Τα βραβεία μας - MSDmsd.gr
- 5MSD (Greece)wikidata.org
- 6MSD任命Mary Srethapakdi为菲律宾董事总经理manilatimes.net
- 7NOXXON与MSD合作开展NOX-A12研究finanznachrichten.de
- 8WEHI 与 MSD 建立研究人员交流合作miragenews.com
- 9FDA 批准 Keytruda 与 Lenvima 联合治疗晚期肾癌pharmatimes.com
- 10BioInvent与MSD达成BI-1808和KEYTRUDA临床试验合作prnewswire.com
- 11Alkermes与MSD达成临床试验合作prnewswire.com
- 12FDA批准Novocure启动KEYNOTE-B36试验的申请finanznachrichten.de
- 13赛诺菲与MSD同意测试THOR-707与Keytruda的联合疗法pharmatimes.com
- 14QBiotics与MSD开展临床合作prnewswire.com
- 15MSD宣布计划收购Takeda的Dunboyne工厂siliconrepublic.com
- 16亚盛医药与默沙东达成临床研究合作finance.sina.com.cn
- 17MSD行使使用Vaxxas疫苗平台的选择权ibtimes.com.au
- 18InxMed与MSD开展临床合作prnewswire.com
Cite this profile: Cite the canonical profile. /brand-wiki/msd · Editorial policy · How profiles are compiled